In the claims

Amend Claims 1 and 19 to read as follows

1. (Twice Amended) A buccal spray composition for transmucosal administration of a pharmacologically active compound

provided that

- a) where the said active compound is soluble in a pharmacologically acceptable polar solvent said composition comprises in weight % of total composition: aqueous polar solvent 30-99.69%, active compound 0.001-60%,
- ai) where said composition in a polar solvent additionally comprises a propellant said composition comprises in total weight % of total composition: a propellant selected from the group consisting of C₃₋₈ hydrocarbon of a linear or branched configuration 2 10%, aqueous polar solvent 10-99%, and active compound 0.1-25%,
- b) where said active compound is soluble in a pharmacologically acceptable non-polar solvent said composition comprises in weight % of total composition: non-polar solvent 30-99.69%, active compound 0.005-55%, and
- bi) where said composition in a non-polar solvent additionally comprises a pharmaceutically acceptable propellant said composition comprises in weight % of total composition: a propellant selected from the group consisting of C₃₋₈ hydrocarbon of a linear or branched configuration 5-80%, non-polar solvent 20-85%, active compound 0.05-50%,

wherein in a), ai), b) and bi) above_ the active compound is selected from the group consisting of biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostoglandins, bronchial dilators selected from the group consisting of terbutaline, and theophylline.

19. (Twice Amended) The composition of Claim 1 wherein the non-polar solvent is a mixture of saturated C_8 and C_{10} triglycerides.